About Us
Stramsen Biotech
Our Vision
To be the global leader in plant-based pharmaceuticals, driving medical advancements that transform lives and shape the future of medicine.
Our Approach
Stramsen Biotech combines scientific expertise with advanced technologies to transform promising plant-based discoveries into innovative pharmaceuticals. We push scientific boundaries, explore new therapeutic frontiers, and develop solutions with the potential to address major unmet medical needs.
Our Portfolio
Total 33 Therapeutic Assets.
Wound Healing
SBX-1977, our lead candidate, targets active healing biology. FDA Pre-IND feedback supports IND submission and the proposed Phase 1 trial.
Prostate Cancer
SBX-1052 and SBX-1068:
Plant-based therapeutics under investigation for prostate enlargement and cancer, respectively.
Oncology
SBX2021 and SBX2022: Exploring the therapeutic potential of multi-plant formulations across solid tumors and blood cancers, respectively.
Cardiovascular Diseases
SBX-2000: Exploring the therapeutic potential of a multi-plant formulation targeting key processes underlying cardiovascular disease.
